Use of sjag1 protein in improving SVF performance

By adding sJAG1 protein to SVF, the cell population was regulated, M2 macrophage polarization was promoted, and inflammatory factors were inhibited, thereby improving the therapeutic performance of SVF and enhancing the therapeutic effect of osteoarthritis and cartilage regeneration capacity.

WO2026238043A1PCT designated stage Publication Date: 2026-11-19SHANGHAI AIBOKANG BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2026/096958
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-14
Filing Date
2026-05-14
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

The quality of existing SVFs varies, resulting in poor treatment outcomes for osteoarthritis.

Method used

By adding sJAG1 protein to regulate the SVF cell population, M2 macrophage polarization is promoted, neutrophil infiltration is inhibited, inflammatory factor production is suppressed, and the anti-inflammatory and tissue repair capabilities of SVF are improved.

Benefits of technology

It improves the therapeutic performance of SVF, enhances the treatment effect of osteoarthritis, and promotes cartilage regeneration and tissue repair.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2026096958_19112026_PF_FP_ABST
    Figure CN2026096958_19112026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to the fields of regenerative medicine and tissue engineering, and in particular, to use of sJAG1 protein in improving SVF performance. Treating osteoarthritis with sJAG1-improved SVF can enhance the anti-inflammatory, tissue repair, and cartilage regeneration capabilities of SVF, thereby improving the therapeutic effect against osteoarthritis.
Need to check novelty before this filing date? Find Prior Art

Description

Use of sJAG1 protein in improving performance of SVF TECHNICAL FIELD

[0001] The present application relates to the field of biotechnology, in particular to the use of sJAG1 protein in improving performance of SVF. BACKGROUND

[0002] Osteoarthritis, also known as degenerative arthritis, is a common disease in the elderly caused by degenerative changes in articular cartilage, joint pain and joint dysfunction (including joint deformity). The commonly used terms such as bone spur, osteoarthritis, and lumbar disc herniation caused by lumbar disc degeneration are all within the scope of osteoarthritis. The main pathological changes of osteoarthritis are degenerative changes and disappearance of cartilage, and reactive hyperplasia of bone spurs at the attachment of joint edge ligament and subchondral bone, which can cause joint pain, stiffness and deformity and dysfunction. The disease can be divided into primary and secondary in clinical practice. Primary osteoarthritis refers to joint disease associated with aging, and secondary osteoarthritis is caused by injury, inflammation, heredity, metabolism, and endocrine diseases. Current treatment methods include non-steroidal anti-inflammatory drug therapy, cell therapy, and surgical therapy, but there are still problems such as high treatment cost and strong side effects.

[0003] SVF, the full name of which is "vascular stromal component", is an effective component extracted from autologous fat tissue of patients, which contains a variety of cells with repair function and a mixture of cytokines to form a cell group. Studies have shown that SVF contains mesenchymal stem cells, M2 macrophages and TGF-β1 that promote chondrocyte regeneration. Therefore, collecting patient's own SVF to treat osteoarthritis is an effective method. However, the quality of SVF is uneven, resulting in poor treatment effect on osteoarthritis. SUMMARY

[0004] Based on the above technical problems, the present application provides a use of sJAG1 in improving the performance of SVF, and a use of SVF improved by sJAG1 in treating osteoarthritis. Experimental results show that sJAG1 can improve the heterogeneity of SVF, promote the polarization of M1 macrophages to M2 macrophages, and prevent neutrophil infiltration by inhibiting the Notch signal transduction pathway, thereby improving the treatment effect of osteoarthritis.

[0005] The specific technical solutions provided by the present application are as follows:

[0006] In a first aspect of the present application, there is provided a use of sJAG1 in improving the performance of SVF. The SVF is a multi-cellular mixture rich in mesenchymal stem cells, macrophages, endothelial cells and various cytokines from the adipose tissue of a patient himself / herself, which is digested by collagenase.

[0007] As a preferred embodiment of the present application, the sJAG1 is used to enhance the anti-inflammatory, tissue repair or chondrogenesis promoting ability of the SVF.

[0008] In a second aspect of the present application, there is provided a pharmaceutical composition, which is a mixture of sJAG1 and SVF, and the ratio of the amount of sJAG1 to SVF in 1 μL of the mixture is 0.08 ng-0.5 ng: 10,000 cells.

[0009] In a third aspect of the present application, there is provided a medicine comprising the pharmaceutical composition.

[0010] As a preferred embodiment of the present application, the medicine has any one of the following uses:

[0011] (1) anti-inflammatory;

[0012] (2) tissue repair;

[0013] (3) chondrogenesis promotion.

[0014] As a preferred embodiment of the present application, the medicine is composed of the pharmaceutical composition as the only active ingredient.

[0015] As a preferred embodiment of the present application, the medicine is composed of the pharmaceutical composition and pharmaceutically acceptable excipients.

[0016] As a preferred embodiment of the present application, the medicine is an injection preparation. The injection preparation is used for intra-capsular injection.

[0017] In a fourth aspect of the present application, there is provided a use of the pharmaceutical composition or the medicine in the preparation of a medicine for treating osteoarthritis.

[0018] Compared with the prior art, the present application has the following advantages:

[0019] The present application finds that the use of sJAG1 in the treatment of osteoarthritis with SVF can improve the treatment performance of SVF. Through the regulation of sJAG1 on the cell population of SVF, the up-regulation of M2 type macrophages, the improvement of the survival rate of ADSC and other cells, and the prevention of neutrophil infiltration, the anti-inflammatory, tissue repair and chondrogenesis promoting ability of SVF can be enhanced, thereby improving the treatment effect of osteoarthritis. BRIEF DESCRIPTION OF DRAWINGS

[0020] Figure 1 is the mRNA expression level of MMP8 gene in SVF treated with sJAG1 and untreated.

[0021] Figure 2 is the detection of immune cell surface marker CD45 in SVF.

[0022] Figure 3 is the staining diagram of sagittal section of joint of untreated mouse after DMM operation.

[0023] Figure 4 is the staining diagram of sagittal section of joint of SVF treated mouse after DMM operation for 2 weeks.

[0024] Figure 5 is the staining diagram of sagittal section of joint of sJAG1 treated mouse after DMM operation.

[0025] Figure 6 is the staining diagram of sagittal section of joint of sJAG1+SVF combined treated mouse after DMM operation. DETAILED DESCRIPTION

[0026] Embodiments of the present application are described in detail below, examples of which are shown in the accompanying drawings, wherein the same or similar reference numerals represent the same or similar elements or elements having the same or similar functions throughout. The embodiments described below by reference to the drawings are exemplary and are intended to explain the present application, and cannot be understood as a limitation of the present application.

[0027] Osteoarthritis is a chronic degenerative joint disease, which eventually shows cartilage degeneration after onset. Current treatment methods include non-steroidal anti-inflammatory drug therapy, cell therapy, surgical therapy, etc., but there are still problems such as high treatment cost and strong side effects.

[0028] SVF is an effective component extracted from autologous fat tissue of patients, which contains a variety of cells with repair function and a mixture of cytokines to form a cell group. Studies have shown that SVF contains mesenchymal stem cells, M2 macrophages and TGF-β1, etc. that promote chondrocyte regeneration. Therefore, collecting patient's own SVF to treat osteoarthritis is an effective method. However, the quality of SVF is uneven, which leads to poor treatment effect on osteoarthritis.

[0029] The invention team of the present application found in research that SVF plays a good role in the treatment of osteoarthritis due to its richness in various cells, growth factors, and immune regulatory factors, etc., and has the ability to promote chondrocyte regeneration and repair. Among them, sJAG1 as a competitive inhibitory ligand of Notch receptor can further inhibit the reduction of M2 macrophages by inhibiting the activation of the Notch signal transduction pathway in OA treatment, prevent neutrophil infiltration in the joint, inhibit the production of inflammatory factors such as TNF-α and IL-1β to slow down inflammation, and can improve the arthritic condition by promoting chondrocyte synthesis to weaken extracellular matrix degradation. Therefore, by adding sJAG1 protein, the quality problem of SVF caused by heterogeneity can be improved, and then osteoarthritis caused by cartilage degeneration and joint capsule cavity environment imbalance can be treated.

[0030] In some embodiments of the present application, SVF is adipose tissue from the patient himself, which is rich in mesenchymal stem cells, macrophages, endothelial cells and various cell factors. It can promote chondrocyte regeneration and inhibit inflammation deterioration through its own differentiation ability and anti-inflammatory components.

[0031] In the present application, "M1 macrophages" refer to macrophage subtypes that are mainly pro-inflammatory, tissue damage, and pathogen repair. "M2 macrophages" refer to macrophage subtypes that are anti-inflammatory, tissue repair, and immune regulation. "Neutrophils" refer to important white blood cells in the immune system.

[0032] In some embodiments of the present application, sJAG1 can inhibit inflammatory factors in SVF, promote the polarization of M1 to M2 type macrophages, promote the secretion of hyaluronic acid, inhibit the degradation of chondrocyte extracellular matrix, and improve the anti-inflammatory, immune regulation, and cartilage repair ability of SVF, thereby improving the effect of treating osteoarthritis.

[0033] In some embodiments of the present application, sJAG1 protein and SVF are co-injected into the joint capsule cavity of patients with osteoarthritis, which can optimize the treatment performance by increasing the number of M2 macrophages and inhibiting the increase in the number of M1 macrophages.

[0034] 1、Materials and methods

[0035] 1.1、Preparation method of rat-derived SVF

[0036] Adipose tissue was collected from 4-week-old C57BL / 6 (purchased from Shanghai Jihui), digested with collagenase I (Bi Yun Tian, ST2294) at 37°C for 30 min, centrifuged at 2000 rpm for 10 min at 4°C after adding one volume of DMEM, and the supernatant was discarded; resuspended in 5 mL of DMEM, centrifuged at 2000 rpm for 10 min at 4°C, and the supernatant was discarded; resuspended in 1 mL of complete medium containing 10% FBS, and then inoculated into a 6 cm culture plate in 5% carbon dioxide at 37°C for 4 h; after discarding the supernatant, washed three times with 1xPBS, and then continued to culture to obtain SVF.

[0037] 1.2, RNA extraction and real-time fluorescent quantitative PCR

[0038] Total RNA was extracted using TRIzol (Takara) according to the pre-set program. RNA reverse transcription and qRTPCR were performed using Vazyme kit. MMP8 primers were obtained from primer bank and ncbi database, and βactin was used as an internal reference for mRNA level.

[0039] 1.3, flow cytometry analysis

[0040] The marker of macrophages in SVF is CD45. After separating SVF, co-culture with sJAG1 for 3 days in a culture dish, collect in 100 μL of 1xPBS, add CD45 antibody (Biolegend, 103107) 4°C, avoid light, incubate for 30 min, centrifuge to remove the supernatant, wash once with 1xPBS, and then detect the rate of CD45 positive cells by machine (LSRFortessa).

[0041] 1.4, construction of medial meniscus instability model (DMM) in mice

[0042] Select 12-week-old and above male mice (purchased from Shanghai Jihui), open the knee joint cavity of the mouse, push away the patella, locate to the medial meniscus, cut off the meniscus tibial ligament, and suture the opened joint capsule cavity, so that the mouse can freely move in the mouse cage for 1.5-2 months. During this period, the mouse cage can be added with a roller to increase the activity of the mouse, so as to better induce OA.

[0043] 1.5, intra-articular injection treatment

[0044] The control group, only SVF injection group, only sJAG1 injection group, and SVF+sJAG1 combination treatment group were divided two weeks after the mouse DMM model surgery. The control group was injected with 5 μL of normal saline; the SVF group was injected with 5 μL of SVF containing 50,000 cells; the sJAG1 treatment group was injected with 5 μL containing 0.5 ng of sJAG1 protein; and the combination treatment group was injected with 5 μL of a mixture containing 50,000 cells of SVF and 0.5 ng of sJAG1. The samples were collected one week after treatment.

[0045] 1.6, OARSI score

[0046] After the sample was collected, the mouse knee joint was fixed in 4% paraformaldehyde for one day, then replaced with EDTA decalcification solution (Biosharp, BL616b) and shaken at room temperature for 10 days, then paraffin-embedded and sectioned, and stained with safranin fast green (Servicebio, G1053) by xylene transparency and ethanol rehydration. The cartilage degeneration was observed under an optical microscope to give an OARSI score.

[0047] 2. Statistical analysis

[0048] Statistical analysis was performed by Windows GraphPad Prism 9.5 (GraphPad Software, Inc., San Diego, CA, USA). All data were obtained from at least three independent experiments and expressed as mean ± standard error of the mean (S.E.M.). Statistical analysis was performed by t-test for two groups or one-way ANOVA with Dunnett's test for multiple groups, and p<0.05 was considered statistically significant.

[0049] 3. Results

[0050] 3.1, sJAG1 inhibits the expression of MMP8 in SVF

[0051] MMP8 is highly expressed in OA and is a metal matrix enzyme with extracellular matrix degradation function. As shown in Figure 1, the present application extracted RNA from SVF and SVF with added sJAG1, reverse transcribed and performed RT-qPCR to verify that the expression of MMP8 in SVF with added sJAG1 was reduced.

[0052] 3.2, sJAG1 increases the proportion of immune cells in SVF

[0053] The SVF is a mixed cell population of adipose stem cells, vascular endothelial cells, macrophages, T cells, etc., among which the highest proportion is macrophages, and M2 macrophages have anti-inflammatory effects. In the paper entitled "Treatment of medication-related osteonecrosis of the jaw with cell therapy" published by Cyril Lucien Bouland et al. in Frontiers in Cell and Developmental Biology, it is recorded that the proportion of CD45+ cells thereof without treatment is 54.6±7.4%, while the present application shows that the proportion of CD45+ cells in the SVF treated by sJAG1 is increased, and it can be further speculated that the SVF can optimize the performance of OA treatment.

[0054] 3.3, the sJAG1 combined SVF group can reduce the condition of mouse OA

[0055] Figs. 3-6 are respectively physiological saline, SVF, sJAG1 and sJAG1+SVF combination injected after C57BL / 6 DMM operation for 2 weeks, and the knee joint of the mouse was collected and stained with safranin fast green one week after treatment, wherein the red part is cartilage tissue, and the green part is bone tissue. As shown in Figs. 3-6, the experimental results of the combination treatment group are more complete than the control group and the single treatment group.

[0056] In summary, the present application shows that sJAG1 can optimize the treatment process of osteoarthritis by promoting the polarization of M1 type macrophages to M2 type macrophages, inhibiting neutrophil infiltration and inhibiting the expression of MMP8 metalloproteinase in SVF.

[0057] The above describes one embodiment of the present application in detail, but the content described is only the preferred embodiment of the present application, and cannot be considered as limiting the scope of the present application. Any equivalent changes and improvements made according to the scope of the present application should still belong to the patent coverage of the present application.

Claims

1. Use of sJAG1 protein in improving the performance of SVF.

2. Use according to claim 1, characterized in that, The sJAG1 protein is used to enhance the anti-inflammatory, tissue repair or chondrogenesis promoting ability of SVF.

3. A pharmaceutical composition, characterized by, The pharmaceutical composition is prepared by mixing the sJAG1 protein of claim 1 with SVF, and the ratio of the sJAG1 protein to SVF in 1 μL of the mixture is 0.08 ng-0.5 ng: 100,000 cells.

4. A medicament, characterized by comprising: It comprises the pharmaceutical composition of claim 3.

5. The medicament according to claim 4, characterized in that, The drug has any of the following uses: (1) Anti-inflammatory; (2) Tissue repair; (3) Chondrogenesis promotion.

6. The medicament according to claim 1, characterized in that, The drug uses the pharmaceutical composition as the only active ingredient.

7. The medicament according to claim 1, characterized in that, The drug is prepared by compounding the pharmaceutical composition with pharmaceutically acceptable adjuvants.

8. The medicament according to claim 7, characterized in that, The drug is an injection preparation.

9. Use of the pharmaceutical composition of claim 3 or the drug of claim 4 in the preparation of a drug for treating osteoarthritis.